NEW YORK (GenomeWeb News) – Bruker BioSciences announced after the close of the market last night that it has completed its acquisition of Bruker BioSpin and has been renamed Bruker Corp.
Roughly 57.5 million shares of new, unregistered Bruker common stock worth around $624.9 million were issued for the stock component of the deal. Combined with the $388 million cash component of the deal, the total value of the acquisition is nearly $100 million more than when Bruker announced its intention to buy BioSpin in early December.
Following completion of the acquisition, Bruker will operate in two segments: the life science and analytical systems segment, and the international advanced superconductor segment.